Comparative effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on prognosis in non-dialysis chronic kidney disease: a propensity-matched cohort study

Renal anemia in patients with stage-IV chronic kidney disease (CKD) is commonly treated with erythropoiesis-stimulating agents (ESAs), which are effective but associated with cardiovascular risks, variable responsiveness, and inflammatory complications. Hypoxia-inducible factor prolyl hydroxylase in...

Full description

Bibliographic Details

Main Authors:	Yi-Chou Hou, Chia-Lin Wu, Wei-Cheng Tseng, Joshua Wang, Kuo-Cheng Lu, Cai-Mei Zheng, Jia-Sin Liu, Ko-Lin Kuo, Der-Cherng Tarng
Format:	Artigo
Language:	Inglês
Published:	Taylor & Francis Group 2025-12-01
Series:	Renal Failure
Subjects:	Chronic kidney disease renal anemia hypoxia-inducible factor prolyl hydroxylase inhibitors erythropoiesis-stimulating agents sepsis
Online Access:	https://www.tandfonline.com/doi/10.1080/0886022X.2025.2592442
Tags:	Add Tag No Tags, Be the first to tag this record!